In vivo suppression of the primary immune response by a species of low density serum lipoprotein.
An apparent subspecies of normal human serum low density lipoprotein (LDL-In) has been identified with suppressive activity for early or facilitating events of human lymphocyte mitogen and allogenic cells stimulation in vitro. This report describes the effects of in vivo administration of LDL-In on the mouse anti-SRBC immune response. Human LDL-In is not species specific and was capable of suppressing the in vivo mouse anti-sheep erythrocyte (SRBC) hemagglutination response by 88% after the administration of 500 to 600 mug LDL-In IV, whereas human serum high density lipoproteins and fibrinogen had no effect. Maximal suppression occurred only when LDL-In was injected 24 to 48 hr before antigen administration. Simultaneous or subsequent injection of LDL-In had no effect. The activity of LDL-In was influenced by antigen dose and maximal at low antigen doses. The number of splenic plaque-forming cells was also reduced indicating a suppression of the clonal expansion of primary B cells to antibody-secreting cells rather than only suppression of antibody synthesis by differentiated B cells and their progeny. These observations suggest the hypothesis that endogenous LDL-In could play an important immunoregulatory role in the maintenance of immune homeostasis and the "natural" suppression of non-productive lymphocyte proliferation.
D000818:Animals; D000917:Antibody Formation; D000941:Antigens; D004306:Dose-Response Relationship, Immunologic; D004912:Erythrocytes / Q000276:immunology; D005340:Fibrinogen / Q000276:immunology; D006462:Hemolytic Plaque Technique; D006801:Humans; D007109:Immunity; D007165:Immunosuppression Therapy; D008075:Lipoproteins, HDL / Q000276:immunology; D008077:Lipoproteins, LDL / Q000276:immunology*; D051379:Mice; D012756:Sheep; D013045:Species Specificity; D013997:Time Factors
D000941:Antigens; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D005340:Fibrinogen